The FDA’s decision to decline approval of Replimune’s treatment for advanced melanoma (RP1) raises important questions about the agency’s current regulatory posture and its alignment with long-standing principles of science-based, patient-focused decision-making.
RP1 demonstrated clinically meaningful activity in a heavily pretreated population, including an overall response rate of approximately 33% and a complete response rate of 15%—outcomes that compare favorably to historical experience with PD-1 monotherapy in this setting. These data were generated in a patient population reflective of real-world clinical practice and are consistent with precedents in oncology where flexibility in evidentiary standards has been appropriately exercised in the context of serious disease and unmet medical need.
The central issue is not whether the FDA should apply rigorous standards—it must. Rather, it is whether those standards are being applied consistently, transparently, and in a manner that allows sponsors to design development programs with confidence that regulatory expectations will remain stable over time.
In this case, the reemergence of concerns regarding trial heterogeneity and the absence of randomized controls—issues that were not clearly determinative during earlier stages of review—suggests a continued lack of alignment between the agency’s guidance and its final decision-making. When regulatory expectations evolve late in the process or are applied in ways that diverge from established precedent, the result is not greater scientific rigor. It is diminished predictability.
That lack of predictability has consequences. Biopharmaceutical development depends on the ability to translate FDA feedback into reproducible, well-designed clinical programs. When that feedback is later revisited or reinterpreted, it introduces uncertainty that extends beyond any single application—affecting capital allocation, development strategy, and ultimately the willingness to invest in innovative approaches targeting complex or high-risk diseases.
Recent leadership transitions have created an opportunity for the agency to recalibrate and restore confidence in its processes. That recalibration will require more than organizational change—it will require a reaffirmation of core regulatory principles: adherence to prior guidance, internal consistency across review divisions and leadership, and a balanced approach that recognizes both scientific nuance and patient need.
For patients with advanced melanoma, today’s decision represents a delay in access to a potentially beneficial therapy. For developers and investors, it reinforces the importance of a regulatory environment that is not only rigorous, but also reliable.
The FDA has long been the global standard for regulatory excellence. Maintaining that position requires a framework that is disciplined, predictable, and anchored in reproducible science. Reestablishing that foundation should remain a central priority as the agency moves forward.
Peter J. Pitts, a former FDA Associate Commissioner, is President of the Center for Medicine in the Public Interest and a Visiting Professor at the University of Paris School of Medicine.
